The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework
Publication: Journal of Comparative Effectiveness Research
Formats available
You can view the full content in the following formats:
References
1.
Unsworth H, Dillon B, Collinson L et al. The NICE evidence standards framework for digital health and care technologies – developing and maintaining an innovative evidence framework with global impact. Digit. Health 7, 20552076211018617 (2021).
2.
Tripathi A, Misra K, Dhanuka R, Singh JP. Artificial intelligence in accelerating drug discovery and development. Recent Pat. Biotechnol. 17(1), 9–23 (2023).
3.
European Medicines Agency. Big Data Steering Group (BDSG): 2022 report. www.ema.europa.eu/en/documents/report/big-data-steering-group-bdsg-2022-report_en.pdf
4.
Department of Health and Social Care. Data saves lives: reshaping health and social care with data. www.gov.uk/government/publications/data-saves-lives-reshaping-health-and-social-care-with-data/data-saves-lives-reshaping-health-and-social-care-with-data
5.
NHS England. NHS Long Term Workforce Plan. www.england.nhs.uk/publication/nhs-long-term-workforce-plan/
6.
National Institute for Health and Care Excellence. Taking a proportionate approach to technology appraisals. www.nice.org.uk/about/what-we-do/proportionate-approach-to-technology-appraisals (2023).
7.
National Institute for Health and Care Excellence. Maintaining and updating our guideline portfolio. www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/maintaining-and-updating-our-guideline-portfolio (2023).
8.
National Institute for Health and Care Excellence. Transforming NICE. https://indepth.nice.org.uk/transforming-nice/index.html (2023).
9.
National Institute for Health and Care Excellence. Early Value Assessment (EVA) for medtech. https://www.nice.org.uk/about/what-we-do/eva-for-medtech (2023).
10.
National Institute for Health and Care Excellence. Managed Access. www.nice.org.uk/about/what-we-do/our-programmes/managed-access (2023).
11.
National Institute for Health and Care Excellence. NICE real-world evidence framework. Corporate Document ECD9 (2022). www.nice.org.uk/corporate/ecd9/chapter/overview
12.
United States Food and Drug Administration. Real-world Evidence. www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence (2023).
13.
European Medicines Agency. High-quality data to empower data-driven medicines regulation in the European Union. www.ema.europa.eu/en/news/high-quality-data-empower-data-driven-medicines-regulation-european-union (2023).
14.
Haute Autorite de Sante. Real-world studies for the assessment of medicinal products and medical devices. Methodology Guide (2021). www.has-sante.fr/jcms/p_3284524/en/real-world-studies-for-the-assessment-of-medicinal-products-and-medical-devices
15.
Canada's Drug and Health Technology Agency. Guidance for Reporting Real-world Evidence. CADTH Methods and Guidelines (2023). www.cadth.ca/guidance-reporting-real-world-evidence
16.
National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. Process and methods [PMG36] (2022). www.nice.org.uk/process/pmg36/
17.
National Institute for Health and Care Excellence. Developing NICE guidelines: the Manual. Process and methods [PMG20] (2023). www.nice.org.uk/process/pmg20/
18.
National Institute for Health and Care Excellence. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. Technology appraisal guidance [TA904] (2023). www.nice.org.uk/guidance/ta904
19.
National Institute for Health and Care Excellence. Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. Technology appraisal guidance [TA883] (2023). www.nice.org.uk/guidance/ta883
20.
National Institute for Health and Care Excellence. FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Diagnostics guidance [DG48] (2023). www.nice.org.uk/guidance/dg48
21.
National Institute for Health and Care Excellence. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. Technology appraisal guidance [TA897] (2023). www.nice.org.uk/guidance/ta897
22.
National Institute for Health and Care Excellence. Digitally enabled therapies for adults with anxiety disorders: early value assessment. Health Technology Evaluation [HTE9] (2023). www.nice.org.uk/guidance/hte9
23.
National Institute for Health and Care Excellence. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. Technology appraisal guidance [TA870] (2023). www.nice.org.uk/guidance/ta870
24.
National Institute for Health and Care Excellence. Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted. Technology appraisal guidance [TA864] (2023). www.nice.org.uk/guidance/ta864
25.
National Institute for Health and Care Excellence. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. Technology appraisal guidance [TA801] (2023). www.nice.org.uk/guidance/ta801
26.
National Institute for Health and Care Excellence. Tezepelumab for treating severe asthma. Technology appraisal guidance [TA880] (2023). www.nice.org.uk/guidance/ta880
27.
National Institute for Health and Care Excellence. Asfotase alfa for treating paediatric-onset hypophosphatasia. Highly Specialised Technologies Guidance [HST23] (2023). www.nice.org.uk/guidance/hst23
28.
National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. Technology appraisal guidance [TA872] (2023). www.nice.org.uk/guidance/ta872
29.
National Institute for Health and Care Excellence. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. Highly Specialised Technologies Guidance [HST22] (2023). www.nice.org.uk/guidance/hst22
30.
National Institute for Health and Care Excellence. Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. Technology appraisal guidance [TA855] (2023). www.nice.org.uk/guidance/ta855
31.
National Institute for Health and Care Excellence. Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. Technology appraisal guidance [TA850] (2022). www.nice.org.uk/guidance/ta850
32.
National Institute for Health and Care Excellence. Regorafenib for previously treated metastatic colorectal cancer. Technology appraisal guidance [TA866] (2023). www.nice.org.uk/guidance/ta866
33.
National Institute for Health and Care Excellence. Fenfluramine for treating seizures associated with Dravet syndrome. Technology appraisal guidance [TA808] (2022). www.nice.org.uk/guidance/ta808
34.
National Institute for Health and Care Excellence. Maribavir for treating refractory cytomegalovirus infection after transplant. Technology appraisal guidance [TA860] (2023). www.nice.org.uk/guidance/ta860
35.
National Institute for Health and Care Excellence. Teduglutide for treating short bowel syndrome. Technology appraisal guidance [TA804] (2022). www.nice.org.uk/guidance/ta804
36.
National Institute for Health and Care Excellence. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. Technology appraisal guidance [TA816] (2022). www.nice.org.uk/guidance/ta816
37.
£1.7m NIHR funding to explore how routinely-collected healthcare data can be used to improve clinical guidance. www.news-medical.net/news/20230223/c2a317m-NIHR-funding-to-explore-how-routinely-collected-healthcare-data-can-be-used-to-improve-clinical-guidance.aspx (2023).
38.
International collaboration – advancing the use of real-world evidence in health technology assessment. www.nice.org.uk/news/blog/international-collaboration-advancing-the-use-of-real-world-evidence-in-health-technology-assessment (2023).
39.
Wang SV, Pottegård A, Crown W et al. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR task force. Value Health 25(10), 1663–1672 (2022).
40.
European Health Data and Evidence Network (EHDEN). www.ehden.eu/ (2023).
41.
Price R, Long G. Challenges in developing and assessing comparative effectiveness evidence for medical technology. In: Decision Making in a World of Comparative Effectiveness Research: A Practical Guide. Birnbaum HG, Greenberg PE (Eds). Adis Singapore, 235–251 (2017).
Information & Authors
Information
Published In
Copyright
© 2023 Crown Copyright. This work is licensed under the www.nationalarchives.gov.uk/doc/open-government-licence/version/3/
History
Received: 18 August 2023
Accepted: 21 August 2023
Published online: 19 October 2023
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework. (2023) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2023-0135
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Joost G.E. Verbeek, Rianne Seefat, Erica A. Wilthagen, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten, Coverage with Evidence Development Programs: A Scoping Review on Characteristics and Patient Access, Health Policy, 10.1016/j.healthpol.2026.105615, (105615), (2026).
- Sophie Hadfield, Marc Zentar, Mark McPhail, Eloise Helme, Rebecca Broderick, Francesca Logan, Robert Loveridge, Emma Madine, Imogen Vining, Julia Wendon, Victoria Metaxa, Daniel Hadfield, Rapid response teams and recommended ward-based management of acute deterioration: a single-centre retrospective cohort study in an inner-city London (UK) teaching hospital, BMJ Open, 10.1136/bmjopen-2025-102016, 15, 9, (e102016), (2025).
- Emanuel Krebs, Deirdre Weymann, Tania Bubela, Dean A. Regier, How life-cycle real-world evidence can bridge evidentiary gaps in precision oncology, Frontiers in Medicine, 10.3389/fmed.2025.1563950, 12, (2025).
- Kitty H F Wong, Robert J Hinchliffe, Target trial emulation: harnessing real-world data to evaluate surgery and perioperative care interventions, British Journal of Surgery, 10.1093/bjs/znaf182, 112, 9, (2025).
- Monisha Dilip, Rohit B. Sangal, Arjun K. Venkatesh, Clinical Quality, Quality Measurement in Healthcare, 10.1002/9781394219421.ch3, (31-46), (2025).
- Adam S. Darwich, Susanne Palmcrantz, Malin Hollmark, Bertil Gonzalez Guve, Evidence for MedTech – the Swedish case of health technology assessment and a new tool to navigate it, Health and Technology, 10.1007/s12553-024-00928-6, 15, 1, (67-80), (2025).
- Ashley Jaksa, Patrick J. Arena, The potential role of real-world evidence in Centers for Medicare & Medicaid Services’ future price negotiations: Recommendations for a robust framework, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2024.30.6.604, 30, 6, (604-607), (2024).
- Benjamin D Bray, Sreeram V Ramagopalan, R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 14, Journal of Comparative Effectiveness Research, 10.57264/cer-2023-0189, 13, 1, (2024).